ALLO
Price
$1.16
Change
-$0.02 (-1.69%)
Updated
May 9 closing price
Capitalization
253.7M
3 days until earnings call
KURA
Price
$5.76
Change
-$0.24 (-4.00%)
Updated
May 9 closing price
Capitalization
498.67M
82 days until earnings call
Ad is loading...

ALLO vs KURA

Header iconALLO vs KURA Comparison
Open Charts ALLO vs KURABanner chart's image
Allogene Therapeutics
Price$1.16
Change-$0.02 (-1.69%)
Volume$3.79M
Capitalization253.7M
Kura Oncology
Price$5.76
Change-$0.24 (-4.00%)
Volume$742.25K
Capitalization498.67M
ALLO vs KURA Comparison Chart
Loading...
ALLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KURA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALLO vs. KURA commentary
May 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALLO is a Hold and KURA is a Hold.

Ad is loading...
COMPARISON
Comparison
May 11, 2025
Stock price -- (ALLO: $1.16 vs. KURA: $5.76)
Brand notoriety: ALLO and KURA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALLO: 117% vs. KURA: 56%
Market capitalization -- ALLO: $253.7M vs. KURA: $498.67M
ALLO [@Biotechnology] is valued at $253.7M. KURA’s [@Biotechnology] market capitalization is $498.67M. The market cap for tickers in the [@Biotechnology] industry ranges from $296.96B to $0. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALLO’s FA Score shows that 0 FA rating(s) are green whileKURA’s FA Score has 1 green FA rating(s).

  • ALLO’s FA Score: 0 green, 5 red.
  • KURA’s FA Score: 1 green, 4 red.
According to our system of comparison, KURA is a better buy in the long-term than ALLO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALLO’s TA Score shows that 4 TA indicator(s) are bullish while KURA’s TA Score has 5 bullish TA indicator(s).

  • ALLO’s TA Score: 4 bullish, 5 bearish.
  • KURA’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, KURA is a better buy in the short-term than ALLO.

Price Growth

ALLO (@Biotechnology) experienced а -31.76% price change this week, while KURA (@Biotechnology) price change was -10.97% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.24%. For the same industry, the average monthly price growth was +9.39%, and the average quarterly price growth was -13.47%.

Reported Earning Dates

ALLO is expected to report earnings on Aug 06, 2025.

KURA is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (-6.24% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KURA($499M) has a higher market cap than ALLO($254M). KURA YTD gains are higher at: -33.869 vs. ALLO (-45.540). KURA has higher annual earnings (EBITDA): -169.5M vs. ALLO (-243.33M). KURA has more cash in the bank: 727M vs. ALLO (292M). KURA has less debt than ALLO: KURA (16.6M) vs ALLO (90.8M). KURA has higher revenues than ALLO: KURA (53.9M) vs ALLO (22K).
ALLOKURAALLO / KURA
Capitalization254M499M51%
EBITDA-243.33M-169.5M144%
Gain YTD-45.540-33.869134%
P/E RatioN/AN/A-
Revenue22K53.9M0%
Total Cash292M727M40%
Total Debt90.8M16.6M547%
FUNDAMENTALS RATINGS
ALLO vs KURA: Fundamental Ratings
ALLO
KURA
OUTLOOK RATING
1..100
420
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
30
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9291
PRICE GROWTH RATING
1..100
9165
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
2350

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KURA's Valuation (30) in the Biotechnology industry is significantly better than the same rating for ALLO (97). This means that KURA’s stock grew significantly faster than ALLO’s over the last 12 months.

KURA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ALLO (100). This means that KURA’s stock grew similarly to ALLO’s over the last 12 months.

KURA's SMR Rating (91) in the Biotechnology industry is in the same range as ALLO (92). This means that KURA’s stock grew similarly to ALLO’s over the last 12 months.

KURA's Price Growth Rating (65) in the Biotechnology industry is in the same range as ALLO (91). This means that KURA’s stock grew similarly to ALLO’s over the last 12 months.

KURA's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ALLO (100). This means that KURA’s stock grew similarly to ALLO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALLOKURA
RSI
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
73%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
72%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
73%
Advances
ODDS (%)
Bullish Trend 9 days ago
80%
Bullish Trend 11 days ago
78%
Declines
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 4 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
84%
Aroon
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
82%
View a ticker or compare two or three
Ad is loading...
ALLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KURA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DNFGX38.910.07
+0.18%
Dunham Focused Large Cap Growth N
PGIAX32.63N/A
N/A
Putnam Focused Equity A
OILVX18.61N/A
N/A
Optimum Large Cap Value Instl
WPGTX17.85N/A
N/A
WPG Partners Small Cap Value Div Fund
HILYX21.12N/A
N/A
Hartford International Value Y